Long-term extension study for participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in JNJ-81201887 parent clinical studies
Geographic Atrophy, secondary to age-related macular degeneration
Study participants who were enrolled and received treatment with low dose JNJ-81201887 in parent clinical studies (81201887MDG2001 [NCT05811351]; 81201887MDG1003) will enter this long-term extension (LTE) study. No study intervention will be administered as part of this study. Study participants who were enrolled and received treatment with high dose JNJ-81201887 in parent clinical studies (81201887MDG2001 [NCT05811351]; 81201887MDG1003) will enter this LTE study. No study intervention will be administered as part of this study. Participants randomised to the sham arm in parent study 81201887MDG2001 (NCT05811351) may have the option to receive JNJ-81201887 open-label treatment under a separate protocol after unmasking that study and will enter this LTE study. No intervention will be administered as part of this study.
1. Participants who were enrolled and received treatment with JNJ-81201887 or sham in a parent clinical study (81201887MDG2001, 81201887MDG1003) 2. Females (women of childbearing potential), male participants, and partners of male participants will not be required to use contraception in this LTE study 3. Must sign an informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study. The ICF may be signed by an impartial witness and/or legally designated representative depending on national/local regulations
There are no exclusion criteria for this LTE study